netFormulary Northern Lincolnshire NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

NHS England - The Cancer Drugs Fund

 

Please refer to the North East Yorkshire and Humber Clinical Alliance for full cancer guidelines and chemotherapy regimens.

North East Yorkshire and Humber Clinical Alliance

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cabozantinib (Cabometyx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund

Tablet

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Capsule

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
   
Dacomitinib (Vizimpro®) )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
NHS England
BlueTeq

Tablet

 
Link  
Link  NICE TA595:Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Tablet

Powder for oral Suspension

 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Tablets

 
Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Tablets

 
Link  NICE TA348: Preventing Rejection in Liver Transplant
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
   
Everolimus (Votubia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Tablet

Dispersible tablet

 
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Tablet

 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

tablet

 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326:Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70:Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Tablet

 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Injection

 
Link  NICE TA334:Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)
Link  NICE TA448:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555:Regorafenib for previously treated advanced hepatocellular carcinoma
   
Ribociclib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Approved for use in line with NICE TA

 
Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Tablet

 
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Capsule

 
Link  MHRA Drug Safety Alert:Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178:Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

infusion

 
Link  NICE TA178: Renal cell carcinoma
   
Tivozanib ((Fotivda®) )
((Fotivda®) )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
BlueTeq

Capsule 

 
Link  NICE TA512:Tivozanib for treating advanced renal cell carcinoma
   
Vemurafenib  ((Zelboraf® ))
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

tablet

 
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Tablets

 
Link  MHRA Drug Safety Alert:Vemurafenib (Zelboraf▼): risk of potentiation of radiation toxicity
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies  

Amber

Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.   

Red

Red-Hospital initiation and continuation only  

Amber Shared Care Protocol

AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised  

Blue

To be supplied from the appropriate commissioned provider.   

Green 2

GREEN 2- to be prescribed by primary care only   

Grey

GREY- NON FORMULARY (As agreed by Area Prescribing Committee)  

netFormulary